- Home
- FMY vs KZIA Comparison
FMY vs KZIA Comparison
Compare FMY & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMY | KZIA |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 56.8M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | FMY | KZIA |
|---|---|---|
| Price | $12.12 | $6.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 3.6K | ★ 215.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.65 | $0.64 |
| 52 Week High | $12.39 | $17.40 |
Technical Indicators
Market Signals| Indicator | FMY | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 48.21 |
| Support Level | $12.06 | $4.91 |
| Resistance Level | $12.18 | $6.14 |
| Average True Range (ATR) | 0.08 | 0.63 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 66.67 | 74.85 |
Price Performance
Historical ComparisonAbout FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.